Latest News & Features
Europe
The unitary patent and UPC would still go ahead, but what would be the impact for the life sciences sector if the UK voted to leave the EU? Victoria Bentley and Helen Cline of Pinsent Masons investigate. 3 December 2015
Americas
Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies. 3 December 2015
Americas
The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc. 2 December 2015
Big Pharma
Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time. 2 December 2015
Medtech
The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices. 1 December 2015
Americas
A group of technology companies has urged the US Supreme Court to re-hear the Nautilus v Biosig case, arguing that the US Court of Appeals for the Federal Circuit failed to apply the “reasonable certainty” standard for determining whether a patent claim is indefinite. 30 November 2015
Asia-Pacific
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company. 27 November 2015
Big Pharma
The English High Court has rejected Pfizer’s attempt to amend a patent that was ruled partially invalid in its long-standing dispute with generics companies Mylan and Allergan. 26 November 2015
Americas
Sandoz has brought to market its generic pregabalin product with a full label in the UK and a skinny label in France. Varuni Paranavitane of Osborne Clarke reports on court rulings in the UK, and most recently France, on actions brought by Warner-Lambert against Sandoz. 26 November 2015
Africa
Fewer IPR petitions are instituted against biotech and pharma patents, and there is a higher survival rate of instituted claims in final written decisions compared to all technical fields combined. Melissa Gibson and Ruben Munoz of Akin Gump analyse the statistics. 26 November 2015